[Corrections] Correction to Lancet Oncol 2018; 19: 580 –81

Grob JJ. Is there any interest in a new BRAF –MEK inhibitor combination in melanoma? Lancet Oncol 2018; 19: 580–81—In the title of this Comment, “BRAF-MEK inhibitor” was spelt incorrectly, and in the fourth paragraph one instance of the drug “encorafenib” was spelt incorrectly and the dose of encorafenib should have been “300 m g”. These corrections have been made to the online version as of April 25, 2018, and the printed Comment is correct.
Source: The Lancet Oncology - Category: Cancer & Oncology Tags: Corrections Source Type: research